The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 03, 2019
Filed:
Sep. 23, 2015
Applicant:
Klinikum Rechts Der Isar Der Tu München, München, DE;
Inventors:
Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 45/06 (2006.01); G01N 33/68 (2006.01); A61K 31/454 (2006.01); A61K 31/713 (2006.01); C12N 15/113 (2010.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
A61K 31/454 (2013.01); A61K 31/713 (2013.01); A61K 45/06 (2013.01); C12N 15/1138 (2013.01); G01N 33/57492 (2013.01); G01N 33/6872 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); C12N 2320/31 (2013.01); G01N 2333/705 (2013.01); G01N 2333/70503 (2013.01); G01N 2800/52 (2013.01);
Abstract
The invention relates to a combination of an immunomodulatory imide drug (IMiD) and an inhibitor of CD147 and/or an inhibitor of MCT1 for use in treating a disease in a subject. It further relates to an inhibitor of CD147 and/or an inhibitor of MCT1 for use in treating a disease in a patient, wherein the patient is IMiD resistant. It further relates to a method of monitoring the efficacy of an IMiD treatment regimen by comparing the protein level of CD147 and/or MCT1 in samples obtained from a subject prior and during IMiD treatment.